Cipla Limited

BSE: 500087 NSE: CIPLA
Cipla Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24239MH1935PLC002380 Incorporated 17 August 1935 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: CIPLA · BSE: 500087 Public Limited Company pharma
Data last updated
Market Cap
₹1,13,019 Cr
CIPLA · NSE
Share Price
₹1,399.70
+0.05% today
Revenue
₹39,012 Cr
FY 2025-26 · +11.7% YoY
EBITDA
₹5,607 Cr
Margin 14.4%
Net Profit
₹3,806 Cr
FY 2025-26 · -26.0% YoY
P/E (TTM)
31.2x
P/B 3.2x
ROE
11.8%
ROCE 15.7%
Debt / Equity
0.02
Interest cover 1.2x

About Cipla Limited

Data last updated: 25 September 2026

Cipla Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 17 August 1935, the company has been in operation for over 91 years.

Registered with ROC Mumbai under CIN L24239MH1935PLC002380. Listed on BSE: 500087 and NSE: CIPLA.

Capital: an authorised share capital of ₹175 Cr and a paid-up capital of ₹161.57 Cr. Formerly known as The Chemical Industrial and Pharmaceutical Laboratories Limited. It is led by directors including Prathivadibhayankara Rajagopalan Ramesh and Mandar Purushottam Vaidya.

Last AGM: 16 July 2025. Financial statements filed for year ended 31 March 2025. Office: Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹39,012 Cr, a growth of 5.33% compared to the previous year. The net worth stands at ₹34,432 Cr (up 10.38% YoY). Total assets are valued at ₹35,561 Cr (up 11.01% YoY).

The company has a workforce of approximately 25,952 employees as per the latest available data. Its group structure includes 9 subsidiaries.

The company is associated with 3 brands - Ciplamed, Mirren, Cipla. As per MCA filings, the company has satisfied charges of ₹68.5 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cipla.com.

Company Details of Cipla Limited
CIN L24239MH1935PLC002380
Registration Number 002380
Incorporation Date 17 August 1935
ROC Mumbai
Listing Status Listed (BSE: 500087, NSE: CIPLA)
Company Status Active
Date of Last AGM 16 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Achin Gupta Managing Director Prathivadibhayankara Rajagopalan Ramesh Director Mandar Purushottam Vaidya Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    cipla.com
  • Social Media
  • Registered Address
    Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013
  • Industry
    Pharma, API Manufacturers, Drug Formulation & Development
Company report
Cipla Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Cipla Limited report

Financials, compliance, directors, charges, ownership and filings for Cipla Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Cipla Limited

Cipla Limited operates multiple associated brands including Ciplamed, Mirren, and Cipla. These brands represent Cipla Limited's diversified market presence and brand portfolio.

Brand Description Website
Ciplamed
Offers online medical news, guidelines, and educational content for professionals. ciplamed.com
Mirren
Natural gas assets are developed alongside innovative pipeline solutions. mirren.co.za
Cipla
APIs, generic drugs, and formulation services are manufactured. cipla.com

Competitors & Alternatives of Cipla Limited

Brands and companies operating in the same space as Cipla Limited include OpenEvidence, Nested Knowledge, QxMD and 5 more.

Competitor Description Location Founded
OpenEvidence OpenEvidence Medical evidence is aggregated and visualized for healthcare professionals. Cambridge, United States, United States 2021
Nested Knowledge Nested Knowledge Clinical evidence platform provided for pharma, device, and research entities. Saint Paul, United States, United States 2018
QxMD QxMD Point-of-care digital tools are developed for healthcare professionals. Vancouver, Canada, Canada 2006
Emerson Ecologics Emerson Ecologics Medicines, supplements, and healthcare products are supplied online. Manchester, United States, United States 1998
Copient Health Copient Health Predictive analysis solutions are provided for healthcare providers. Alpharetta, United States, United States 2019
EMedicine EMedicine Medical reference information is published online for healthcare professionals. New York, United States, United States 1996
The Clinics The Clinics App offering clinical resources Maryland Heights, United States, United States 1999
iDoctus iDoctus Medical app providing drug searches, interactions, and clinical tools for healthcare professionals. Spain, United States, United States 2011

Business Activity of Cipla Limited

Cipla Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
G Trade G1 Wholesale Trading Locked
Premium access

Business activity turnover details for Cipla Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Board of Directors of Cipla Limited

Cipla Limited is currently managed by 10 directors, with 30 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Prathivadibhayankara Rajagopalan Ramesh
Also directs: Nestle India Limited, Crompton Greaves Consumer Electricals Limited, Itc Hotels Limited and 5 more
Director 01 Jul 2021 5 Years 2 Months Current
Mandar Purushottam Vaidya Director 29 Jul 2022 4 Years 1 Months Current
Yusuf Khwaja Hamied
Also directs: Famid Sports Private Limited
Director 21 Jul 1972 54 Years 2 Months Current
Adil Zainulbhai
Also directs: Network18 Media & Investments Limited, Reliance Retail Limited, Unnati Employment Network and 2 more
Director 23 Jul 2014 12 Years 2 Months Current
Kamil Hamied
Also directs: Alps Remedies Private Limited, Famid Sports Private Limited
Director 01 Nov 2024 1 Years 10 Months Current
Maya Hari Director 01 Nov 2024 1 Years 10 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Cipla Limited FY 2025-26 filings available

Cipla Limited reported revenue of ₹39,012 Cr (up 5.33% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹39,012 Cr
+5.3% YoY
EBITDA
₹5,607 Cr
-21.3% YoY
Profit After Tax
₹3,806 Cr
-26.0% YoY
Net Worth
₹34,432 Cr
+10.4% YoY
Total Assets
₹35,561 Cr
+11.0% YoY
Total Debt
₹614 Cr
+40.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue39,01237,03935,41530,93829,71928,22717,132
Revenue growth+11.7%+2.0%+12.4%+2.9%+5.7%+72.2%+5.0%
EBITDA5,6077,1286,0964,8454,3714,2523,206
EBITDA margin+14.4%+19.2%+17.2%+15.7%+14.7%+15.1%+18.7%
Profit before tax5,2246,8215,7024,0383,4933,2902,178
Net profit3,8065,1464,2072,8422,5822,3691,458
Net profit margin+9.8%+13.9%+11.9%+9.2%+8.7%+8.4%+8.5%
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
Balance sheet
Total assets35,56132,03527,62124,78522,42520,87819,351
Net worth34,43231,19326,70623,40820,84218,32715,763
Total debt6144385598031,0562,0142,816
Cash & bank1,3078008751,5651,9281,4011,004
Net working capital9,68510,6589,6749,2008,0846,9466,744
Cash flow
Cash from operations3,9405,0054,1343,2383,3263,7553,068
Cash from investing(2,234)(3,682)(2,982)(2,376)(1,858)(2,374)114
Cash from financing(1,234)(1,293)(1,200)(958)(1,600)(1,240)(2,949)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1196,5417,0747,5896,9576,7307,0737,051
Revenue growth (YoY)+3.5%-2.0%+0.0%+7.0%+3.2%+8.5%+7.0%+5.7%
Other income211148206269259289222191
EBITDA1,1929559791,8951,7781,5381,9891,886
EBITDA margin+16.8%+14.8%+14.1%+25.4%+26.0%+23.3%+28.6%+27.1%
Depreciation304383278297253309280272
Interest17.0313.1314.0313.1814.0514.0214.6415.40
Profit before tax1,0827078931,8541,7701,5041,9161,789
Tax295157219500478279332483
Net profit7875506751,3531,2921,2251,5841,306
EPS (₹)9.766.868.3616.7216.0615.1219.4316.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20,06519,95217,48315,05815,38111,30312,659
Revenue growth+12.0%+9.0%+9.3%+1.9%+41.7%-17.3%+0.8%
EBITDA4,1915,7784,4843,1673,7113,0672,707
EBITDA margin+20.9%+29.0%+25.7%+21.0%+24.1%+27.1%+21.4%
Profit before tax4,6366,4695,3103,3753,8803,2082,964
Net profit3,4424,8134,0382,5552,9092,4292,227
Net profit margin+17.2%+24.1%+23.1%+17.0%+18.9%+21.5%+17.6%
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
Balance sheet
Total assets34,66732,41428,17424,87522,71820,19017,679
Net worth34,20132,09927,97424,63822,51419,92817,403
Total debt12511745.5550.0923.4552.126.06
Cash & bank5192783339661,428875523
Net working capital7,3188,3687,6287,9156,6455,5185,579
Cash flow
Cash from operations2,8323,3013,7273,0352,7733,4602,018
Cash from investing(1,344)(2,309)(2,883)(2,758)(2,464)(3,361)(1,127)
Cash from financing(1,322)(1,074)(709)(425)(427)(65.80)(694)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5,0784,2104,4985,2265,0464,7984,9714,775
Revenue growth (YoY)+3.8%-9.7%+3.0%+13.2%+20.0%+23.5%+8.9%+6.3%
Other income243180417255271588189289
Total expenses3,9923,6434,0213,7033,4223,4793,3093,337
EBITDA1,0865674771,5231,6241,3191,6621,438
EBITDA margin+23.2%+14.8%+11.2%+33.9%+36.1%+31.0%+40.2%+36.2%
Depreciation169218153141146148143146
Interest5.686.744.032.655.883.493.553.00
Profit before tax1,1545227361,6331,7441,7561,7041,578
Tax291138119423441270266400

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 25 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7,1196,5417,0747,5896,9576,7307,0737,051
Revenue growth (YoY)+3.5%-2.0%+0.0%+7.0%+3.2%+8.5%+7.0%+5.7%
Other income211148206269259289222191
EBITDA1,1929559791,8951,7781,5381,9891,886
EBITDA margin+16.8%+14.8%+14.1%+25.4%+26.0%+23.3%+28.6%+27.1%
Depreciation304383278297253309280272
Interest17.0313.1314.0313.1814.0514.0214.6415.40
Profit before tax1,0827078931,8541,7701,5041,9161,789
Tax295157219500478279332483
Net profit7875506751,3531,2921,2251,5841,306
EPS (₹)9.766.868.3616.7216.0615.1219.4316.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue39,01237,03935,41530,93829,71928,22717,132
Revenue growth+11.7%+2.0%+12.4%+2.9%+5.7%+72.2%+5.0%
Other income882862747475281266344
Total expenses33,40529,91129,31926,09325,34923,97513,926
Employee cost5,3664,8334,3103,8303,5303,2523,027
EBITDA5,6077,1286,0964,8454,3714,2523,206
EBITDA margin+14.4%+19.2%+17.2%+15.7%+14.7%+15.1%+18.7%
Depreciation1,2111,1071,0511,1721,0521,0681,175
Interest54.3962.0189.88110106161197
Profit before tax5,2246,8215,7024,0383,4933,2902,178
Tax1,3541,5301,5471,203934889631
Net profit3,8065,1464,2072,8422,5822,3691,458
Net profit margin+9.8%+13.9%+11.9%+9.2%+8.7%+8.4%+8.5%
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital162162161161161161161
Reserves & surplus34,27031,03226,54523,24620,68018,16515,602
Shareholders' funds (net worth)34,43231,19326,70623,40820,84218,32715,763
Minority interest88.2995.8095.90306276259294
Secured loans0.0011.9891.77429376392423
Unsecured loans6144264683746801,6222,393
Total debt6144385598031,0562,0142,816
Total liabilities35,56132,03527,62124,78522,42520,87819,351
Assets
Gross block23,42219,55318,14617,12216,96815,78715,151
Net block12,43410,0069,6079,1609,6839,5169,683
Capital work in progress2,0421,5661,1531,093766969825
Investments8,2237,9335,4493,6622,5512,7101,471
Inventories6,5975,6425,2385,1565,3504,6694,378
Sundry debtors5,6205,5064,7714,0573,4243,4463,891
Cash & bank balances1,3078008751,5651,9281,4011,004
Loans & advances2,9424,0073,7022,9371,8131,4071,417
Total current assets16,46615,95614,58513,71512,51610,92310,690
Total current liabilities6,7825,2984,9124,5154,4323,9773,946
Net working capital9,68510,6589,6749,2008,0846,9466,744
Total assets35,56132,03527,62124,78522,42520,87819,351
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash543512561658790649508
Net cash from operating activities3,9405,0054,1343,2383,3263,7553,068
Net cash from investing activities(2,234)(3,682)(2,982)(2,376)(1,858)(2,374)114
Net cash from financing activities(1,234)(1,293)(1,200)(958)(1,600)(1,240)(2,949)
Net change in cash47330.31(48.99)(96.78)(132)141234
Closing cash1,3078008751,5651,9281,4011,004
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.3%+4.6%+14.5%+4.1%+5.3%+64.8%+4.7%
EBITDA growth-21.3%+16.9%+25.8%+10.8%+2.8%+32.6%+3.5%
PBT growth-23.4%+19.6%+41.2%+15.6%+6.2%+51.1%+4.8%
Net income growth-26.0%+22.3%+48.0%+10.1%+9.0%+62.5%+3.6%
Revenue CAGR (3Y)+8.0%+7.6%+7.9%+21.8%+22.0%+23.0%+6.0%
EBITDA CAGR (3Y)+5.0%+17.7%+12.8%+14.8%+12.2%+15.7%+9.0%
Profitability & leverage
Net income margin+9.9%+14.3%+11.7%+9.2%+8.6%+8.5%+9.0%
Return on capital employed+15.7%+23.2%+22.3%+17.8%+16.8%+17.4%+12.2%
Return on net worth+11.8%+18.3%+16.6%+12.8%+13.1%+14.1%+10.1%
Debt / equity0.020.020.030.040.080.140.23
Long-term debt / equity0.010.010.010.020.050.110.20
Interest cover1.241.031.782.983.205.059.72
Efficiency & per share
Fixed asset turnover1.821.962.011.821.811.821.18
Inventory turnover6.386.816.815.895.936.244.11
Debtors turnover7.017.218.028.278.657.694.26
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
Dividend per share (₹)13.0016.0013.008.505.005.004.00
Book value per share (₹)426.24386.25330.79290.01258.33227.25195.51
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5,0784,2104,4985,2265,0464,7984,9714,775
Revenue growth (YoY)+3.8%-9.7%+3.0%+13.2%+20.0%+23.5%+8.9%+6.3%
Other income243180417255271588189289
Total expenses3,9923,6434,0213,7033,4223,4793,3093,337
EBITDA1,0865674771,5231,6241,3191,6621,438
EBITDA margin+23.2%+14.8%+11.2%+33.9%+36.1%+31.0%+40.2%+36.2%
Depreciation169218153141146148143146
Interest5.686.744.032.655.883.493.553.00
Profit before tax1,1545227361,6331,7441,7561,7041,578
Tax291138119423441270266400
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20,06519,95217,48315,05815,38111,30312,659
Revenue growth+12.0%+9.0%+9.3%+1.9%+41.7%-17.3%+0.8%
Other income1,1231,2791,434826742654893
Total expenses15,87414,17412,99911,89111,6708,2359,952
Employee cost3,3503,0552,6892,3812,1221,7041,911
EBITDA4,1915,7784,4843,1673,7113,0672,707
EBITDA margin+20.9%+29.0%+25.7%+21.0%+24.1%+27.1%+21.4%
Depreciation658574588596547469600
Interest19.3015.1120.2522.2726.9345.0736.05
Profit before tax4,6366,4695,3103,3753,8803,2082,964
Tax1,1211,3111,233862922739646
Net profit3,4424,8134,0382,5552,9092,4292,227
Net profit margin+17.2%+24.1%+23.1%+17.0%+18.9%+21.5%+17.6%
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital162162161161161161161
Reserves & surplus34,04031,93827,81224,47722,35219,76617,242
Shareholders' funds (net worth)34,20132,09927,97424,63822,51419,92817,403
Secured loans0.000.000.000.000.000.000.00
Unsecured loans12511745.5550.0923.4552.126.06
Total debt12511745.5550.0923.4552.126.06
Total liabilities34,66732,41428,17424,87522,71820,19017,679
Assets
Gross block10,5008,6708,0467,7667,3887,0666,698
Net block5,1943,8783,7193,8093,9104,0664,151
Capital work in progress978638670504268355320
Investments17,61617,35113,79411,90910,9749,7267,190
Inventories4,3543,6073,2543,2773,4863,0863,021
Sundry debtors3,3973,8602,6822,8882,7943,0353,560
Cash & bank balances5192783339661,428875523
Loans & advances2,8753,7744,2053,4671,5881,1911,088
Total current assets11,14411,52010,47410,6009,2968,1878,193
Total current liabilities3,8263,1522,8462,6852,6512,6692,613
Net working capital7,3188,3687,6287,9156,6455,5185,579
Total assets34,66732,41428,17424,87522,71820,19017,679
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash82.7416529.4817729526264.47
Net cash from operating activities2,8323,3013,7273,0352,7733,4602,018
Net cash from investing activities(1,344)(2,309)(2,883)(2,758)(2,464)(3,361)(1,127)
Net cash from financing activities(1,322)(1,074)(709)(425)(427)(65.80)(694)
Net change in cash166(81.78)135(148)(117)33.18197
Closing cash5192783339661,428875523
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+0.6%+14.1%+16.1%-2.1%+36.1%-10.7%+2.3%
EBITDA growth-27.5%+28.9%+41.6%-14.7%+21.0%+13.3%+8.2%
PBT growth-28.3%+21.8%+57.3%-13.0%+21.0%+8.2%+18.9%
Net income growth-28.5%+19.2%+58.0%-12.2%+19.8%+9.1%+23.1%
Revenue CAGR (3Y)+10.0%+9.1%+15.7%+6.0%+7.5%-0.3%+5.5%
EBITDA CAGR (3Y)+9.8%+15.9%+13.5%+5.4%+14.1%+13.1%+19.3%
Profitability & leverage
Net income margin+17.5%+25.9%+23.3%+16.7%+19.2%+21.8%+18.3%
Return on capital employed+13.9%+21.4%+20.1%+14.3%+18.2%+14.7%+17.8%
Return on net worth+10.6%+17.2%+15.5%+10.7%+13.9%+13.0%+14.0%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.550.290.520.870.851.731.71
Efficiency & per share
Fixed asset turnover2.092.392.211.992.131.641.97
Inventory turnover5.045.825.354.454.683.704.30
Debtors turnover5.536.106.285.305.283.433.76
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
Dividend per share (₹)13.0016.0013.008.505.005.004.00
Book value per share (₹)423.39397.46346.49305.25279.05247.10215.85
Want more history and ratios?
You're viewing the latest exchange-filed financials for Cipla Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Cipla Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 29.20%, foreign institutional investors hold 20.20%, domestic institutional investors hold 34.60%, retail and other public shareholders hold 16.00% of Cipla Limited.

Promoters: 29.20%DII (Domestic Institutional): 34.60%FII (Foreign Institutional): 20.20%Retail & Others: 16.00%
Jun 2026
QUARTER
29.20% Promoters
34.60% DII (Domestic Institutional)
20.20% FII (Foreign Institutional)
16.00% Retail & Others
Promoter holding - history
Now 29.20% · Jun 2026High 29.20% · Sep 2025Low 29.20% · Sep 2025
28%28.8%29.5%30.3%31%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 29.20%Dec 2025: 29.20%Mar 2026: 29.20%Jun 2026: 29.20%29.20%29.20%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters29.20%29.20%29.20%29.20%
Public70.80%70.80%70.80%70.80%

Group Structure of Cipla Limited

Cipla Limited has 9 subsidiary companies and 7 associated companies. This group structure data is as of FY 2025. The corporate group structure reflects Cipla Limited's business expansion strategy and organizational complexity.

9
Subsidiary companies
7
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Meditab Specialities Limited U23240MH1996PLC104442 -
Cipla Health Limited U24100MH2015PLC267880 -
Goldencross Pharma Limited U24239MH2000PLC123766 -
Cipla Pharma And Life Sciences Limited U24239MH2008PLC381559 -
Cipla Pharmaceutical S Limited U24239MH2019PLC333266 -
Jay Precision Pharmaceutical S Private Limited U33111MH2012PTC234037 -

Showing major subsidiaries. Total: 9.

Charges & Borrowings of Cipla Limited

Open charges
₹0
Satisfied charges
₹68.5 Cr
Breakdown by lending institutions
The Hongkong and Shanghai Banking Corporation Limited (Lead Charge Holder)₹68.50 Cr
Latest charge details
DateLenderAmountStatus
17 Apr 1986 The Hongkong and Shanghai Banking Corporation Limited (Lead Charge Holder) ₹68.5 Cr Satisfied

Total charge records: 1 View all charges

Employees and EPFO Compliance at Cipla Limited

Cipla Limited has a workforce of 25,952 employees as of Oct 08, 2025.

Employee count
25,952
Active EPFO establishments
3
Employee growth
4.75%
Premium access

Employee and EPFO history for Cipla Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Cipla Limited

Premium access

GST registrations and filing compliance for Cipla Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Cipla Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Cipla Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Cipla Limited

Premium access

MSME payment history for Cipla Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Cipla Limited

Premium access

Corporate group structure for Cipla Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Cipla Limited

Premium access

MCA filings and documents for Cipla Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Cipla Limited

Directors
29 Apr 2026
Achin Gupta was appointed as a Ceo on 29 Apr 2026 & has been associated with this company since 4 months 29 days.
Directors
01 Apr 2026
Achin Gupta was appointed as a Managing Director on 01 Apr 2026 & has been associated with this company since 5 months 26 days.
Activity
16 Jul 2025
Cipla Limited last Annual general meeting of members was held on 16 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Cipla Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Directors
01 Nov 2024
Kamil Hamied was appointed as a Director on 01 Nov 2024 & has been associated with this company since 1 year 10 months.
Directors
01 Nov 2024
Maya Hari was appointed as a Director on 01 Nov 2024 & has been associated with this company since 1 year 10 months.

Recent News on Cipla Limited

Frequently Asked Questions about Cipla Limited

Cipla Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 17 August 1935 (91+ years old) and is registered under CIN L24239MH1935PLC002380. Listed on BSE: 500087 and NSE: CIPLA. The company has 25,952 employees.

Cipla Limited reported revenue of ₹39,012 Cr for FY 2025-26 (up 5.33% YoY) based on consolidated financials.

The current directors of Cipla Limited are:

The primary industry of Cipla Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Cipla Limited is listed on both BSE (code: 500087) and NSE (symbol: CIPLA).

Cipla Limited can be reached at the registered office: Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013, or through the website cipla.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available